歐康維視生物-B(01477.HK)完成購買Alimera股份
格隆匯4月23日丨歐康維視生物-B(01477.HK)公吿,於達成股份購買協議的所有條件後,股份購買協議項下的交易已根據股份購買協議的條款及條件於2021年4月15日完成。於有關完成後,合共114.5萬股新Alimera股份已按認購價約每股Alimera股份8.73美元發行及配發予公司。於完成股份購買協議項下的交易後,Alimera由公司擁有約16.6%權益。
Alimera為一家總部位於美國的生物製藥公司,專門從事商業化及開發影響眼睛後部或視網膜疾病的處方眼科藥物。Alimera於截至2020年12月31日止兩個年度的除税後淨虧損分別為1040萬美元及530萬美元。Alimera於截至2020年12月31日的持份者虧絀總額約為800萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.